Kyverna Therapeutics, Inc. vs LB Pharmaceuticals Inc — Valuation Comparison 2026
Access all valuation models for KYTX vs LBRX — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.
Access Full Analysis — From $27/mo →LBRX scores higher with a 4.6/10 quality rating vs KYTX's 4.2/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.
Comparing Kyverna Therapeutics, Inc. (KYTX) and LB Pharmaceuticals Inc (LBRX) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.
KYTX currently trades at $8.65 with a QOC of 4.2/10, while LBRX trades at $27.53 with a QOC of 4.6/10.
Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).